You are here: Geisinger Medical
Laboratories > Test
Catalog
Geisinger Medical Laboratories/Geisinger Proven Diagnostics Test Catalog
PROTHROMBIN (FACTOR II) GENE MUTATION, PCR |
||
ORDERING INFORMATION: |
Geisinger Epic Procedure Code: LAB2943 Geisinger Epic ID: 53656 | |
SPECIMEN COLLECTION |
||
Specimen type: |
Whole Blood | |
Preferred collection container: |
||
Specimen required: |
3 mL lavendar-top EDTA whole blood; minimum 0.5 mL. NO SHARED SPECIMENS WITH OTHER LABORATORY DEPARTMENTS. May be combined with other Molecular Diagnostic tests. For genetic testing, original tube required. | |
Special notes: |
Mix well immediately. | |
| SPECIMEN PROCESSING |
||
Specimen processing instructions: |
Do not centrifuge. | |
Transport temperature: |
Refrigerate (2-8°C). | |
Specimen stability: |
Stable at room temperature for 24 hours; stable at 2-8°C (refrigerated) for 15 days. | |
Rejection criteria: |
Stability limits exceeded. Shared or comingled specimens. | |
TEST DETAILS |
||
Reference interval: |
Negative. | |
Additional information: |
For genetic testing, original tube required. | |
CPT code(s): |
81240 | |
| Note: The billing party has sole responsibility for CPT coding. Any questions regarding coding should be directed to the payer being billed. The CPT codes provided by GML are based on AMA guidelines and are for informational purposes only. | ||
Test includes: |
Prothrombin gene mutation, | |
Methodology: |
Real-time Polymerase Chain Reaction (PCR) |
|
Synonyms: |
Factor II, factor II DNA analysis, prothrombin gene mutation, factor II PCR, factor II mutation, PGM PCR, PGM mutation, PGM DNA, factor II DNA, G20210A mutation PPGM
|
|
Clinical significance: |
The G20210A mutation in the prothrombin (factor II) gene is the second most common inherited risk factor for venous thrombosis and is associated with elevated prothrombin concentrations. Heterozygous, or individuals who have one copy of the mutation, are at a 3- to 6-fold increased risk for venous thrombosis. Homozygotes, or individuals who have two copies of the mutation, are at an even higher risk. | |
Doctoral Director(s:) |
Yi Ding MD, PhD | |
| Review Date: | 12/20/2022 | |